↑ Rising
Business
SELLAS Life Sciences stock soars 240% on positive cancer trial
SELLAS Life Sciences shares surged 240% after its REGAL trial showed promise for a leukemia vaccine, then slid 10% on a $150 million stock offering.
3 trends tracked about this subject — the full history, oldest to newest below.
SELLAS Life Sciences shares surged 240% after its REGAL trial showed promise for a leukemia vaccine, then slid 10% on a $150 million stock offering.
Federal regulators and state authorities allege Martin Shkreli violated a lifetime pharmaceutical industry ban.
The FTC and seven states have moved to hold Martin Shkreli in contempt for allegedly breaching his lifetime ban on pharmaceutical industry activity.